Table 2

Association of SREBP-2 gene polymorphisms between the AVN patients and controls
Loci
 Sub-group
 Genotype
Allele 2 vs. 1
 Codominant Heterozy
 Dominant
 Recessive













11
 12
 22
 MAF

(11 vs 12 vs 22)*
 12 + 22 vs. 11
 22 vs. 11 + 12












OR (95% CI)
 P†
 OR (95% CI)
 P†
 OR (95% CI)
 P†
 OR (95% CI)
 P†
IVS1+8408 T>C
TT
 CT
 CC



















(rs2267439)
 CTL
 77
 138
 55
 0.459








AVN
 159
 218
 66
 0.395
 0.751
(0.604–0.935)
 0.010
 0.744
(0.595–0.930)
 0.009
 0.702
(0.504–0.978)
 0.036
 0.647
(0.433–0.964)
 0.033
IVS3-342 G>T
GG
 GT
 TT



















(rs2269657)
 CTL
 146
 107
 16
 0.258








AVN
 241
 149
 32
 0.263
 1.069
(0.835–1.369)
 0.596
 1.070
(0.834–1.372)
 0.595
 1.039
(0.762–1.415)
 0.810
 1.305
(0.697–2.442)
 0.406
IVS11+414 G>A
GG
 AG
 AA



















(rs1052717)
 CTL
 132
 120
 19
 0.292








AVN
 202
 186
 53
 0.331
 1.207
(0.954–1.525)
 0.117
 1.206
(0.954–1.525)
 0.118
 1.133
(0.835–1.539)
 0.423
 1.796
(1.034–3.120)
 0.038
IVS12-1667 G>A
GG
 AG
 AA



















(rs2267443)
 CTL
 116
 121
 29
 0.337








AVN
 169
 192
 69
 0.384
 1.265
(1.006–1.590)
 0.044
 1.259
(1.003–1.579)
 0.047
 1.254
(0.916–1.718)
 0.157
 1.589
(0.996–2.535)
 0.052

*11: homozygotes for the major allele, 12: heterozygotes and 22: homozygotes for the minor allele.

† Logistic regression analyses were used for calculating. bold: P value < 0.05

Kim et al. BMC Medical Genetics 2008 9:94   doi:10.1186/1471-2350-9-94